anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Endometriosis is a major source of morbidity for U.S. females, affecting \~49% of adolescents with chronic pelvic pain and 10% of all women of reproductive age. This percentage translates into approximately 176 million women worldwide who may suffer from endometriosis. Annual health care costs are estimated to be over $22 billion in the US alone. Over 50% of adults with endometriosis report onset of severe pelvic pain during their adolescence. Symptoms result in decreased quality of life, negative socioeconomic consequences, impaired reproductive potential, and diminished mental health. Endometriosis is a chronic disease that progresses over time in more than half of patients. Endometriosis has no cure. For adolescents in particular, this means that the impact of endometriosis and its symptoms can last for decades. Appropriate management involves not only prompt initiation of therapy, but also the maintenance of therapy for a protracted length of time.

Medical therapy for endometriosis typically includes oral progestins or contraceptive pills. Though often effective, these options are associated with systemic side-effects which may further affect compliance and preclude long-term use. Furthermore, the need for repeated or regular administration compromises compliance and therefore efficacy. The levonorgestrel-releasing intrauterine system (LNG-IUD) has been evaluated as a promising treatment for endometriosis in adult women. The LNG-IUD 52 mg (Mirena) delivers levonorgestrel (LNG) to the uterine cavity at a steady rate of 20 µg/day over 5 to 6 years. The LNG causes atrophy and pseudo decidualization of the uterine lining, along with apoptosis of endometrial glands and stroma. As the LNG-IUD requires no further patient action following insertion, patient compliance is excellent. While continuation of the device is generally very good in adults, unfavorable uterine bleeding patterns are the most frequent reason for early device removal, particularly within the first 6 months. Anecdotal clinical experience suggests that combining use of the LNG-IUD with low-dose oral progestin therapy may maximize effectiveness and continuation of the LNG-IUD device in adolescents.

The investigators will recruit 80 adolescents for participation in a double-blind, randomized trial of NETA (n=40) vs. placebo (control group, n=40) for adjunct treatment to the levonorgestrel-containing IUD for pelvic pain due to endometriosis. It is believed that a combination of the locally-acting LNG-IUD plus systemic NETA may be the optimal combination to effectively treat endometriosis pain, minimize side effects, provide contraception, and control bleeding for adolescents with endometriosis.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse reactions reported in ≥2% of patients in placebo-controlled clinical studies and at a rate greater than placebo are shown in Table 2. These studies had a treatment duration of up to 12 weeks.

Other adverse reactions reported in clinical studies were abdominal pain, dizziness, hypersensitivity (including rash, pruritus, urticaria, and angioedema) and pancreatitis. The following laboratory abnormalities have also been reported: dipstick-positive proteinuria and microscopic hematuria; elevated creatine phosphokinase, transaminases, glucose, glutamyl transpeptidase, alkaline phosphatase, and bilirubin; and thyroid function abnormalities.

In the METEOR study, patients were treated with CRESTOR 40 mg (n=700) or placebo (n=281) with a mean treatment duration of 1.7 years. Adverse reactions reported in ≥2% of patients and at a rate greater than placebo are shown in Table 3.

In the JUPITER study, patients were treated with CRESTOR 20 mg (n=8,901) or placebo (n=8,901) for a mean duration of 2 years. In JUPITER, there was a significantly higher frequency of diabetes mellitus reported in patients taking CRESTOR (2.8%) versus patients taking placebo (2.3%). Mean HbA1c was significantly increased by 0.1% in CRESTOR-treated patients compared to placebo-treated patients. The number of patients with a HbA1c >6.5% at the end of the trial was significantly higher in CRESTOR-treated versus placebo-treated patients [see Clinical Studies (14)].

Adverse reactions reported in ≥2% of patients and at a rate greater than placebo are shown in Table 4.

Pediatric Patients with HeFH

In a 12‑week controlled study in pediatric patients 10 to 17 years of age with HeFH with CRESTOR 5 mg to 20 mg daily [see Use in Specific Populations (8.4) and Clinical Studies (14)], elevations in serum CK greater than 10 x ULN were observed more frequently in CRESTOR-treated patients compared with patients receiving placebo. Four of 130 (3%) patients treated with CRESTOR (2 treated with 10 mg and 2 treated with 20 mg) had increased CK greater than 10 x ULN, compared to 0 of 46 patients on placebo.
No significant effect of age on the clearance of ultrafilterable platinum has been observed. In the adjuvant therapy colon cancer randomized clinical trial, [see Clinical Studies (14)] 723 patients treated with oxaliplatin injection and infusional 5-fluorouracil/leucovorin were <65 years and 400 patients were ≥65 years. A descriptive subgroup analysis demonstrated that the improvement in DFS for the oxaliplatin injection combination arm compared to the infusional 5-fluorouracil/leucovorin alone arm appeared to be maintained across genders. The effect of oxaliplatin injection in patients ≥65 years of age was not conclusive. Insufficient subgroup sizes prevented analysis by race. Patients ≥ 65 years of age receiving the oxaliplatin injection combination therapy experienced more grade 3 and 4 granulocytopenia than patients < 65 years of age (45% versus 39%).  
  
In the previously untreated for advanced colorectal cancer randomized clinical trial [see Clinical Studies (14)] of oxaliplatin injection, 160 patients treated with oxaliplatin injection and 5-fluorouracil/leucovorin were < 65 years and 99 patients were ≥65 years. The same efficacy improvements in response rate, time to tumor progression, and overall survival were observed in the ≥65 year old patients as in the overall study population. In the previously treated for advanced colorectal cancer randomized clinical trial [see Clinical Studies (14)] of oxaliplatin injection, 95 patients treated with oxaliplatin injection and 5-fluorouracil/leucovorin were <65 years and 55 patients were ≥65 years. The rates of overall adverse reactions, including grade 3 and 4 events, were similar across and within arms in the different age groups in all studies. The incidence of diarrhea, dehydration, hypokalemia, leukopenia, fatigue and syncope were higher in patients ≥65 years old. No adjustment to starting dose was required in patients ≥65 years old.
FIELD: hair dying facilities. SUBSTANCE: composition comprises, in carrier appropriate for keratin materials: a)laccase-type ferment; b) anionic surfactant selected from the group comprising acylizetionates, acyltaurates, sulfosuccinates of special structure, acylsarcosinates of special structure, acylglutamates, polyoxyalkylated hydroxycarboxylic acids or salts thereof, glucamidalkylsulfates, alkylgalactosyduronates, anionic derivatives of alkylpolyglucosides or mixtures thereof; c) dye fixed by oxidation. Method involves using said composition and set of keratin dying facilities. Composition, method and set of dying facilities provide for uniform, intensive and chromatic dying without substantial destruction or decolorization of keratin fibers and improved stability to reactive effects. EFFECT: convenient use, improved quality of dying by means of said composition. 26 cl, 1 tbl
The method of natural tooth color assessment included the use of the spectrophotometer Spectroshade Micro (MHT Zurich, Switzerland), which is a reflectance spectrophotometer with a LED technology light source with an output of 410-680 nm that is transformed into monochromatic light (λ = 400-720 nm) by means of grating. On this type of spectrophotometers, light is split so that teeth can be illuminated simultaneously from two sides at a 45° angle with the use of an intra-oral camera. The reflected light is directed at 0° on two detector areas (each detector area surface is of 18 x 13 mm2). One detector area is a color CCD chip responsible for the generation of the colored video image. A black-and-white CCD detector area records the spectrophotometric data. During a measuring process, light originating from the monochromator of the device is emitted in 10-nm intervals. Resulting images consist of 300,000 pixels. Initially, CIE tristimulus values are calculated and then converted to CIE-Lab values with the use of the accompanying software. Prior to every measuring cycle, the spectrophotometer had to be calibrated to a white and a green ceramic tile that are incorporated on the base of the device by the manufacturer.

Assessments were performed with closed lips in order to exclude disturbance by daylight. In order to avoid methodical errors in the assessment of luminance teeth of the upper and lower dental arches were not in contact, thereby obtaining a uniform black background by the oral cavity without an overlapping of anterior teeth. Tooth color was measured in the study and in the control groups at Time point 1 and Time Point 2. To enhance reliability of the method two sequential pictures of each tooth (Left + Right) were obtained with the use of the spectrophotometer and imported to the dedicated MHT Spectroshade software v3.01 Build 1007a (MHT Zurich, Switzerland), licensed to Aristotle University (Station ID: 952317337-Serial NR LUA164-164-164). Using the synchronization tool followed by the synchronous measurement tool, the cursor was accurately positioned on the center of the clinical crown on both pictures simultaneously, and the software reported color measurements for both pictures. The cursor shape was a circle, while the size was set at 100 pixels. Due to the synchronization of the pictures, the cursor area was exactly the same for both. To consider the method reliable, the maximal allowed color difference between the two consecutive pictures, was set at ΔΕ≤1.
PROBLEM TO BE SOLVED: To obtain a cosmetic material having an excellent promotion effect on hair growth, a moisture keeping property, an increasing action on the subcutaneous blood flow rate, etc., and suitable for hair growth and skin care, etc., by containing a specific N-acylamino acid ester. SOLUTION: This cosmetic material contains an N-acylamino acid eater having an acyl group with an odd number of carbon atoms as an active ingredient. The N-acylamino acid ester is an ester between an N-acyl amino acid obtained by an acylation of an amino acid (e.g.; glutamic acid) having at least one acyl group with the odd number of carbon atoms such as 7-19 (e.g.; N- acylglutamic acid and an alcoholic compound (e.g.; ethanol). This is obtained by a known esterifying reaction. The acylmino acid ester is contained by 0.01-20wt.% based on the total amount of the composition. Thus, the solubility to a solvent becoming a base of the cosmic material is extremely improved.
The Research Domain Criteria (RDoC) initiative was established by the US National Institute of Mental Health as a multilevel, disorder-agnostic framework for analysis of human psychopathology through designated domains and constructs, including the "Positive Valence Systems" domain focused on reward-related behavior. This study investigates the reward valuation subconstruct of "effort" and its association with genetic markers, functional neurobiological pathways, and polygenic risk scores for psychopathology in 1215 children aged 6-12 and their parents (n = 1044). All participants completed the effort expenditure for rewards task (EEfRT), which assesses "effort" according to two quantitative measures: hard-task choice and reward sensitivity. Genetic association analyses were undertaken in MAGMA, utilizing EEfRT outcome variables as genome-wide association studies phenotypes to compute SNP and gene-level associations. Genome-wide association analyses found two distinct genetic loci that were significantly associated with measures of reward sensitivity and a separate genetic locus associated with hard task choice. Gene-set enrichment analysis yielded significant associations between "effort" and multiple gene sets involved in reward processing-related pathways, including dopamine receptor signaling, limbic system and forebrain development, and biological response to cocaine. These results serve to establish "effort" as a relevant construct for understanding reward-related behavior at the genetic level and support the RDoC framework for assessing disorder-agnostic psychopathology.
The CERAMAX COC 36mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The insert is available in several inner diameter sizes, including 36mm; only 36mm inserts will be utilized in this PAS. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper.
Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse.
The efficacy of PEMRYDI RTU was evaluated in Study JMCH (NCT00005636), a multicenter, randomized (1:1), single-blind study conducted in patients with MPM who had received no prior chemotherapy. Patients were randomized (n=456) to receive PEMRYDI RTU 500 mg/m2 intravenously over 10 minutes followed 30 minutes later by cisplatin 75 mg/m2 intravenously over two hours on Day 1 of each 21-day cycle or to receive cisplatin 75 mg/m2 intravenously over 2 hours on Day 1 of each 21-day cycle; treatment continued until disease progression or intolerable toxicity. The study was modified after randomization and treatment of 117 patients to require that all patients receive folic acid 350 mcg to 1,000 mcg daily beginning 1 to 3 weeks prior to the first dose of PEMRYDI RTU and continuing until 1 to 3 weeks after the last dose, vitamin B12 1,000 mcg intramuscularly 1 to 3 weeks prior to first dose of PEMRYDI RTU and every 9 weeks thereafter, and dexamethasone 4 mg orally, twice daily, for 3 days starting the day prior to each PEMRYDI RTU dose. Randomization was stratified by multiple baseline variables including KPS, histologic subtype (epithelial, mixed, sarcomatoid, other), and gender. The major efficacy outcome measure was overall survival and additional efficacy outcome measures were time to disease progression, overall response rate, and response duration. 

A total of 448 patients received at least one dose of protocol-specified therapy; 226 patients were randomized to and received at least one dose of PEMRYDI RTU plus cisplatin, and 222 patients were randomized to and received cisplatin. Among the 226 patients who received cisplatin with PEMRYDI RTU, 74% received full supplementation with folic acid and vitamin B12 during study therapy, 14% were never supplemented, and 12% were partially supplemented. Across the study population, the median age was 61 years (range: 20 to 86 years); 81% were male; 92% were White, 5% were Hispanic or Latino, 3.1% were Asian, and < 1% were other ethnicities; and 54% had a baseline KPS score of 90-100% and 46% had a KPS score of 70-80%. With regard to tumor characteristics, 46% had Stage IV disease, 31% Stage III, 15% Stage II, and 7% Stage I disease at baseline; the histologic subtype of mesothelioma was epithelial in 68% of patients, mixed in 16%, sarcomatoid in 10% and other histologic subtypes in 6%. The baseline demographics and tumor characteristics of the subgroup of fully supplemented patients was similar to the overall study population. 

The efficacy results from Study JMCH are summarized in Table 18 and Figure 9.

Table 18: Efficacy Results in Study JMCH

Figure 9: Kaplan-Meier Curves for Overall Survival in Study JMCH

Based upon prospectively defined criteria (modified Southwest Oncology Group methodology) the objective tumor response rate for PEMRYDI RTU plus cisplatin was greater than the objective tumor response rate for cisplatin alone. There was also improvement in lung function (forced vital capacity) in the PEMRYDI RTU plus cisplatin arm compared to the control arm.
The coronavirus disease 2019 (COVID-19) pandemic has unquestionably transformed the field of intensive care medicine. Never have we witnessed millions of patients develop acute respiratory failure in such a short span of time. This led to extensive resource constraints and difficulty in treating patients. However, this also gave rise to several innovations that have spurred the development and progress of intensive care medicine as a specialty. In this chapter, we explore an overview of frailty, the impact of frailty in patients with severe COVID-19 respiratory failure, and the available supports, by summarising the current literature. This chapter also discusses the lessons learnt from each of the sections that can be applied to daily clinical practice. The chapter also proposes insights into future research.
Subjects will be randomized to receive single dose of Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 1 and Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
FIELD: cosmetology. SUBSTANCE: the present innovation deals with cosmetic compositions containing combined copolymer of methacrylic acid and C 1 -C 4 -alkylacrylate in cosmetically acceptable medium, and oil chosen among synthetic ones, esters of C 3 -C 14 -acids containing, as a whole, below 20 carbon atoms, vegetable oils where the content of palmitoleic acid is either above or equal to 0.2 weight% against oil weight. The compositions mentioned are used, in particular, to wash and/or take care of keratin materials such as hair or skin. Moreover, hair becomes of good cosmetic properties, for example, improved capacity for brushing, better lightness, smoothness and softness, etc. It is, also, suggested the method for washing and, also, a conditioner - the abovementioned combined copolymer of methacrylic acid and C 1-4 -alkylacrylate. EFFECT: higher efficiency. 35 cl, 1 ex, 1 tbl
The research protocol includes detailed food intake analysis, including timing and composition, markers related to the neuroendocrine pathway cortisol, and observations of individually experienced symptoms. Moreover, the study also explores intestinal injury and endotoxemia parameters, such as I-FABP, CLDN-3, and LBP. As a first goal, this study investigates the timing and composition of food intake concerning changes in gut integrity, cortisol levels, and gastrointestinal symptoms. Investigators explored whether an athlete's nutritional intake influences any GI disturbance induced by high-intensity exercise. As a second goal, Investigators tried to connect symptoms and markers from both pathways with gastrointestinal complaints. Investigators hypothesised that cortisol levels would be more profound than other studied parameters in gastrointestinal symptoms.
A water soluble or water dispersible bolus article suitable for oral administration to a ruminant animal comprising a seaweed extract enriched in bromoform is described. The bolus article is generally a rumen bolus article. The seaweed extract enriched in bromoform is a methanolic extract or an oil extract of seaweed. The bromoform constitutes at least 60% of the seaweed extract by weight. The seaweed extract is lyophilised seaweed extract. The seaweed extract is an extract of an Asparagopsis species of seaweed. A method of reducing methane production in ruminant animals is also described.
Disclosed is a method for manufacturing a clay mineral-metal oxide composite powder for blocking ultraviolet rays. The method for manufacturing a clay mineral-metal oxide composite powder may prepare a clay mineral-metal oxide composite powder by mixing nanoparticles of a metal oxide capable of blocking ultraviolet rays in a clay mineral suspension dispersed with clay mineral particles or a precursor material of the metal oxide to prepare a spray solution, and spray-drying the spray solution. In this case, the metal oxide may have a band gap that absorbs light in an ultraviolet ray region and transmits light in a visible ray region. When the clay mineral-metal oxide composite powder is applied to a composition for blocking ultraviolet rays, it is possible to remarkably reduce a direct contact between metal oxide nanoparticles and a human body. Also, the metal oxide nanoparticles may be fundamentally prevented from penetrating into the human body. Thus, human body stability of the composition can be significantly improved.
The placebo is applied the same acupuncture points, each stick apply time 2h, once each day. Acupoints selected: Yanglingquan, Dubi, Neixiyan. The treatment lasted for 4 weeks.
PURPOSE: Emergency laparotomy is associated with high morbidity for the surgical patient. Understanding patients' health-related quality of life after their surgery is important to enhance the informed consent process, and to enable the evaluation and improvement of surgical care. This review aims to summarise the use of health-related quality of life tools in clinical trials involving patients undergoing emergency laparotomy.
METHODS: A systematic review was undertaken of the scientific literature published in the MEDLINE® and PubMed databases between January 2011 and July 2021. A narrative synthesis approach was chosen to synthesise the diverse range of studies in a structured manner. All included papers were evaluated using the Cochrane Collaboration's tool for assessing risk of bias.
RESULTS: Eleven studies were selected for inclusion. Most of the studies had a low risk of bias. Two of the studies used health-related quality of life as the primary outcome measure. A variety of health-related quality of life measurement tools were used; the EQ-5D tool was the most popular questionnaire. Protocol adherence was dependent on the length of time which had elapsed after emergency surgery.
CONCLUSION: There are many perceived challenges to collecting health-related quality of life data in the emergency surgery setting. Many of these can be offset with progressive trial designs. There is a need for further research in the systematic development of patient-reported outcomes for use in emergency surgery.
To provide an agent for promoting collagen production, comprising a novel component derived from natural sources as an active ingredient, a medicament, cosmetics, and a method for manufacturing an agent for promoting collagen production.SOLUTION: The present invention provides an agent for promoting collagen production, comprising a fermentation product of a Lamiaceae plant. The present invention provides a medicament that comprises an agent for promoting collagen production, comprising a fermentation product of a Lamiaceae plant. The present invention provides cosmetics that comprise an agent for promoting collagen production, comprising a fermentation product of a Lamiaceae plant. The present invention provides a method for manufacturing an agent for promoting collagen production, comprising fermenting a Lamiaceae plant. The Lamiaceae plant may be an Isodon plant.The Isodon plant may be Isodon japonicus HARA or Rabdosia japonica HARA, also called Isodonis Herba. Collagen may be type I collagen.SELECTED DRAWING: None